222. Primary nephrotic syndrome
234 clinical trials,   241 drugs   (DrugBank: 78 drugs),   59 drug target genes,   185 drug target pathways
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2008-001647-19-NL (EUCTR) | 22/05/2008 | 04/06/2008 | Treatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study. - ACTHiMeN | Treatment with synthetic adrenocoticotropic hormone (ACTH) in patients with membranous nephropathy and high risk for renal failure. A pilot study. - ACTHiMeN | Membranous nephropathy MedDRA version: 9.1;Level: LLT;Classification code 10027170;Term: Membranous nephropathy | Trade Name: Synacthen Depot 1mg | Radboud University Nijmegen Medical Center | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands |